Teva Pharmaceuticals, established in 1901, is a global pharmaceutical company. The company is into development, production and marketing of a wide range of specialty medicines, generic and OTC products, active pharmaceutical ingredients (API) and nov... More
ZYDUS LIFESCIENCES TEVA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
ZYDUS LIFESCIENCES Mar-23 |
TEVA PHARMA Dec-13 |
ZYDUS LIFESCIENCES/ TEVA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 495 | 3,459 | - | |
Low | Rs | 319 | 3,005 | - | |
Sales per share (Unadj.) | Rs | 170.3 | 1,985.4 | - | |
Earnings per share (Unadj.) | Rs | 19.8 | 124.0 | - | |
Cash flow per share (Unadj.) | Rs | 26.9 | 284.5 | - | |
Dividends per share (Unadj.) | Rs | 6.00 | 108.57 | - | |
Avg Dividend yield | % | 1.5 | 3.4 | 43.9% | |
Book value per share (Unadj.) | Rs | 173.0 | 2,205.4 | - | |
Shares outstanding (eoy) | m | 1,012.20 | 848.00 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 2.4 | 1.6 | 146.9% | |
Avg P/E ratio | x | 20.6 | 26.1 | 79.0% | |
P/CF ratio (eoy) | x | 15.1 | 11.4 | 133.1% | |
Price / Book Value ratio | x | 2.4 | 1.5 | 160.5% | |
Dividend payout | % | 30.3 | 87.5 | 34.7% | |
Avg Mkt Cap | Rs m | 412,144 | 2,741,007 | 15.0% | |
No. of employees | `000 | NA | 44.9 | 0.0% | |
Total wages/salary | Rs m | 24,564 | 0 | - | |
Avg. sales/employee | Rs Th | 0 | 37,459.7 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 2,340.1 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 172,374 | 1,683,624 | 10.2% | |
Other income | Rs m | 4,746 | 0 | - | |
Total revenues | Rs m | 177,120 | 1,683,624 | 10.5% | |
Gross profit | Rs m | 29,677 | 461,061 | 6.4% | |
Depreciation | Rs m | 7,227 | 136,089 | 5.3% | |
Interest | Rs m | 1,299 | 33,069 | 3.9% | |
Profit before tax | Rs m | 25,897 | 291,903 | 8.9% | |
Minority Interest | Rs m | 0 | 1,326 | 0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | -191,619 | -0.0% | |
Tax | Rs m | 5,878 | -3,564 | -164.9% | |
Profit after tax | Rs m | 20,019 | 105,175 | 19.0% | |
Gross profit margin | % | 17.2 | 27.4 | 62.9% | |
Effective tax rate | % | 22.7 | -1.2 | -1,859.1% | |
Net profit margin | % | 11.6 | 6.2 | 185.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 100,082 | 1,137,114 | 8.8% | |
Current liabilities | Rs m | 55,267 | 991,659 | 5.6% | |
Net working cap to sales | % | 26.0 | 8.6 | 300.9% | |
Current ratio | x | 1.8 | 1.1 | 157.9% | |
Inventory Days | Days | 50 | 91 | 55.4% | |
Debtors Days | Days | 94 | 96 | 97.5% | |
Net fixed assets | Rs m | 144,776 | 549,909 | 26.3% | |
Share capital | Rs m | 1,012 | 4,144 | 24.4% | |
Net worth | Rs m | 175,158 | 1,870,187 | 9.4% | |
Long term debt | Rs m | 0 | 860,875 | 0.0% | |
Total assets | Rs m | 244,940 | 3,847,621 | 6.4% | |
Interest coverage | x | 20.9 | 9.8 | 213.0% | |
Debt to equity ratio | x | 0 | 0.5 | 0.0% | |
Sales to assets ratio | x | 0.7 | 0.4 | 160.8% | |
Return on assets | % | 8.7 | 3.6 | 242.2% | |
Return on equity | % | 11.4 | 5.6 | 203.2% | |
Return on capital | % | 15.5 | 4.9 | 314.8% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 26,888 | 268,283 | 10.0% | |
From Investments | Rs m | 11,712 | -95,063 | -12.3% | |
From Financial Activity | Rs m | -44,004 | -321,823 | 13.7% | |
Net Cashflow | Rs m | -5,338 | -148,604 | 3.6% |
Compare ZYDUS LIFESCIENCES With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US)
Compare ZYDUS LIFESCIENCES With: LASA SUPERGENERICS DECCAN HEALTH CARE ANG LIFESCIENCES INDIA GUJ.TERC LAB MEDICO REMEDIES
Asian shares slipped before a Bank of Japan policy decision where authorities are likely to bring an end to the world's last negative rates regime.